Tandem Short Long Term Debt Total from 2010 to 2024

TNDM Stock  USD 31.22  1.18  3.93%   
Tandem Diabetes Short and Long Term Debt Total yearly trend continues to be very stable with very little volatility. Short and Long Term Debt Total is likely to grow to about 436.5 M this year. During the period from 2010 to 2024, Tandem Diabetes Short and Long Term Debt Total quarterly data regression pattern had sample variance of 28460.8 T and median of  58,944,000. View All Fundamentals
 
Short and Long Term Debt Total  
First Reported
2012-12-31
Previous Quarter
477.1 M
Current Value
475.9 M
Quarterly Volatility
171.7 M
 
Yuan Drop
 
Covid
Check Tandem Diabetes financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Tandem Diabetes' main balance sheet or income statement drivers, such as Depreciation And Amortization of 8 M, Interest Expense of 6 M or Selling General Administrative of 370.1 M, as well as many indicators such as Price To Sales Ratio of 2.44, Dividend Yield of 0.0 or PTB Ratio of 4.71. Tandem financial statements analysis is a perfect complement when working with Tandem Diabetes Valuation or Volatility modules.
  
Check out the analysis of Tandem Diabetes Correlation against competitors.

Latest Tandem Diabetes' Short Long Term Debt Total Growth Pattern

Below is the plot of the Short Long Term Debt Total of Tandem Diabetes Care over the last few years. It is Tandem Diabetes' Short and Long Term Debt Total historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Tandem Diabetes' overall financial position and show how it may be relating to other accounts over time.
Short Long Term Debt Total10 Years Trend
Slightly volatile
   Short Long Term Debt Total   
       Timeline  

Tandem Short Long Term Debt Total Regression Statistics

Arithmetic Mean143,929,713
Geometric Mean60,140,937
Coefficient Of Variation117.21
Mean Deviation146,044,371
Median58,944,000
Standard Deviation168,703,334
Sample Variance28460.8T
Range432.2M
R-Value0.86
Mean Square Error8087.7T
R-Squared0.74
Significance0.000043
Slope32,365,746
Total Sum of Squares398451.4T

Tandem Short Long Term Debt Total History

2024436.5 M
2023415.7 M
2022419.9 M
2021314.7 M
2020228.3 M
201820.4 M
201776.5 M

About Tandem Diabetes Financial Statements

Tandem Diabetes investors utilize fundamental indicators, such as Short Long Term Debt Total, to predict how Tandem Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Short and Long Term Debt Total415.7 M436.5 M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Tandem Diabetes Care is a strong investment it is important to analyze Tandem Diabetes' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Tandem Diabetes' future performance. For an informed investment choice regarding Tandem Stock, refer to the following important reports:
Check out the analysis of Tandem Diabetes Correlation against competitors.
You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tandem Diabetes. If investors know Tandem will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tandem Diabetes listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.37)
Earnings Share
(2.02)
Revenue Per Share
13.082
Quarterly Revenue Growth
0.314
Return On Assets
(0.1)
The market value of Tandem Diabetes Care is measured differently than its book value, which is the value of Tandem that is recorded on the company's balance sheet. Investors also form their own opinion of Tandem Diabetes' value that differs from its market value or its book value, called intrinsic value, which is Tandem Diabetes' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tandem Diabetes' market value can be influenced by many factors that don't directly affect Tandem Diabetes' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tandem Diabetes' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tandem Diabetes is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tandem Diabetes' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.